Hepatocellular Carcinoma Non-resectable Clinical Trials

22 recruiting

Frequently Asked Questions

Common questions about Hepatocellular Carcinoma Non-resectable clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 2

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Hepatocellular Carcinoma Non-resectableHCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest55 enrolled12 locationsNCT04522544
Recruiting
Phase 2

Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University320 enrolled1 locationNCT06904183
Recruiting
Phase 2

Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable
Queen's Medical Center80 enrolled1 locationNCT04965454
Recruiting
Phase 2

Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University78 enrolled1 locationNCT06904196
Recruiting

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD300 enrolled2 locationsNCT05713994
Recruiting
Phase 2

Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion

Liver CancerHepatocellular CarcinomaHepatocellular Cancer+2 more
Asan Medical Center138 enrolled1 locationNCT05992220
Recruiting
Phase 2

DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University130 enrolled1 locationNCT06397235
Recruiting
Phase 2

Atezolizumab and Bevacizumab with Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable
Chang Gung Memorial Hospital45 enrolled1 locationNCT06133062
Recruiting
Phase 3

Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University178 enrolled1 locationNCT06492395
Recruiting
Phase 2

Y-90 SIRT for Unresectable HCC Larger Than 7cm

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University33 enrolled2 locationsNCT06707233
Recruiting
Not Applicable

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma Non-resectable
Terumo Europe N.V.50 enrolled10 locationsNCT05911633
Recruiting
Phase 2

Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable
Tongji Hospital36 enrolled1 locationNCT06187961
Recruiting
Phase 2

mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria

Hepatocellular Carcinoma Non-resectable
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University29 enrolled1 locationNCT06607107
Recruiting

Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)

Hepatocellular Carcinoma Non-resectable
Fujian Provincial Hospital28 enrolled4 locationsNCT06561399
Recruiting
Not Applicable

TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Liver MetastasesCholangiocarcinoma Non-resectableLiver Malignant Tumors+1 more
Tianjin Medical University Cancer Institute and Hospital40 enrolled1 locationNCT06487663
Recruiting
Phase 2

Atezolizumab/Bevacizumab Followed by On-demand TACE or Initial Synchronous Treatment With TACE and Atezolizumab/Bevacizumab

Hepatocellular Carcinoma Non-resectable
Ludwig-Maximilians - University of Munich106 enrolled7 locationsNCT04224636
Recruiting

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma Non-resectable
Tongji Hospital300 enrolled4 locationsNCT05717738
Recruiting
Phase 2

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University23 enrolled1 locationNCT06397222
Recruiting
Phase 2

Ivonescimab Combined With HAIC for the Treatment of Unresectable Hepatocellular Carcinoma(uHCC).

Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectable
Tianjin Medical University Cancer Institute and Hospital30 enrolled1 locationNCT06375486
Recruiting
Phase 3

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University258 enrolled1 locationNCT05985798